Precision Therapeutics Forms TumorGenesis Inc. Subsidiary to Focus on the Next Generation of Patient Derived Tumor Models

MINNEAPOLIS, Feb. 27, 2018 (GLOBE NEWSWIRE) Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), formerly Skyline Medical (NASDAQ:SKLN), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today it has formed a wholly owned subsidiary, TumorGenesis Inc., to develop the next generation or patient derived (“PDx”) tumor models for precision cancer therapy and drug development. The Company formed TumorGenesis Inc. to develop a new, rapid approach to growing tumors in the laboratory, which essentially The post Precision Therapeutics Forms TumorGenesis Inc. Subsidiary to Focus on the Next Generation of Patient Derived Tumor Models appeared first on Public Wire.
http://bit.ly/2EVcBln